We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Medmen Enterprises Inc (CE) | USOTC:MMNFF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.000001 | 0.000001 | 0.000001 | 39,450 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address, including zip code, of principal executive offices)
Registrant’s telephone number, including area code | ( |
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On January 19, 2024, Ellen Harrison notified the board of directors (the “Board”) of MedMen Enterprises Inc. (the “Company”) of her resignation from her positions as the Company’s Chief Executive Officer and as a member of the Board, effective immediately. Ms. Harrison’s resignation was not the result of any disagreements with the Company on any matter related to the operations, policies, or practices of the Company.
On January 24, 2024, Michael Serruya, the Executive Chairman of the Board, who has served on the Board since August 2021, also resigned from the Board, effective immediately. Upon the effectiveness of his resignation, Mr. Serruya also ceased to serve on any Board committees, including as a member and Chairman of the Nominating & Corporate Governance Committee and as a member of the Audit Committee and the Compensation Committee. Mr. Serruya’s resignation was not the result of any disagreements with the Company on any matter related to the operations, policies, or practices of the Company.
Item 7.01 | Regulation FD Disclosure. |
On January 24, 2024, the Company issued a press release announcing the events described in Item 5.02 above. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished with this Item 7.01 and Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
Item 8.01 | Other Events. |
On January 23, 2024, the Board appointed Richard Ormond as the Chief Restructuring Officer for the Company. Mr. Ormond has over 20 years of experience that includes business law, real estate, banking, receivership, cannabis regulations, commercial litigation, and restructuring.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit Number |
Description | |
99.1 | Press Release issued on January 24, 2024 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 24, 2024 | MEDMEN ENTERPRISES INC. | |
/s/ Kimble Cannon | ||
By: | Kimble Cannon | |
Its: | General Counsel & Corporate Secretary |
Exhibit 99.1
PRESS RELEASE
MEDMEN ANNOUNCES management and Board changes
BOCA RATON, Fla— (January 24, 2024) — MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company today announced that Ellen Deutsch Harrison has stepped down as the Chief Executive Officer and a Board member effective January 19, 2024 and the Board has appointed Richard Ormond as Chief Restructuring Officer. Furthermore, Michael Serruya, Executive Chairman of the Board, who has served on the Board since August 2021, has stepped down from the Board effective today.
ABOUT MEDMEN:
MedMen (CSE: MMEN, OTCMKTS: MMNFF) is a premier American cannabis company dedicated to improving life with Cannabis for All. With operations across the United States in California, Nevada, Illinois, Arizona, Massachusetts, and New York, MedMen is known for its leading MedMen® and LuxLyte® brands offering cannabis in consumer-preferred product forms for medical and recreational use. MedMen produces and curates the best consumer product assortment for retail operations in its local communities, and drives consumer loyalty with service and engaging in-store experience, combined with reward, delivery, and e-commerce programs. For more information please visit www.medmen.com.
MEDIA CONTACT: La Nida Cedeno LaNida.Cedeno@medmen.com
INVESTOR CONTACT: investors@medmen.com
Cover |
Jan. 19, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 19, 2024 |
Entity File Number | 000-56199 |
Entity Registrant Name | MEDMEN ENTERPRISES INC. |
Entity Central Index Key | 0001776932 |
Entity Tax Identification Number | 98-1431779 |
Entity Incorporation, State or Country Code | A1 |
Entity Address, Address Line One | 6501 Congress Ave. |
Entity Address, City or Town | Boca Raton |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33487 |
City Area Code | 424 |
Local Phone Number | 330-2082 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
1 Year Medmen Enterprises (CE) Chart |
1 Month Medmen Enterprises (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions